EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy

Song Xue, Sabrina Kraus, Johanna S Enke, Kerstin Michalski, Marcus Hacker, Hermann Einsele, Andreas K Buck, Constantin Lapa, Xiang Li iD, Niklas Dreher

European Journal of Nuclear Medicine and Molecular Imaging · 2026-06 · 53 (7) · 4560-4571

DOI: 10.1007/s00259-026-07814-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 18.02.2026. Verfasst von Song Xue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienn…. Hauptthemen laut MEDLINE: Receptors, CXCR4, Multiple Myeloma, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

C-X-C motif chemokine receptor 4 (CXCR4)-directed radiopharmaceutical therapy (RPT) represents a promising option for hematologic malignancies. Nevertheless, responses in relapsed and refractory (r/r) multiple myeloma (MM) are heterogenous, emphasizing the need for optimized patient selection before RPT. Current approaches mostly rely on qualitative assessments, confirming relevant CXCR4-expression by CXCR4-directed PET in vital myeloma burden, the latter usually being determined by additional [ 18 F]FDG-PET.

Purpose

To evaluate whether quantitative imaging biomarkers derived from dual-tracer PET/CT can enhance patient stratification and predict therapeutic response and survival following CXCR4-RPT. Materials and methods 22 patients with r/r MM who underwent CXCR4-directed [⁶⁸Ga]Ga-PentixaFor-PET/CT and [¹⁸F]FDG-PET/CT imaging prior to CXCR4-RPT were retrospectively analyzed. A fully automated pipeline performed deep-learning–based lesion segmentation and dual-tracer fusion; batch quality control and correction ensured segmentation accuracy and concordant-lesion adjudication (> 10% volumetric overlap) prior to lesion-level feature extraction. Features included demographics, laboratory/genetic variables, and imaging metrics from FDG- and CXCR4-PET, stratified by anatomic site (medullary vs. extramedullary) and concordance (concordant vs. discordant as defined by comparing FDG- and CXCR4-positive myeloma lesions). Surface-standardized maximum inter-lesion distances (sDmax) were additionally computed. Endpoints were therapy response (responder vs. non-responder as defined by serological response assessment based on IMWG-criteria or PET/MRI based response assessment) and overall survival (OS). Group comparisons were performed using Welch’s t-test/Chi-square; survival analysis was conducted applying Kaplan–Meier estimates and log-rank tests. Decision-tree models were interpreted with SHapley Additive exPlanations (SHAP).

Results

Responders to RPT showed lower [ 18 F]FDG-SUV mean in medullary and extramedullary concordant lesions (Welch’s p = 0.03). In the response classifier, these metrics ranked among the top predictors by SHAP, alongside selected extramedullary CXCR4-dominant discordant features and high-risk cytogenetics. Shorter OS was associated with higher TLG[FDG medullary concordant], greater sDmax[FDG], and higher CXCR4-positive medullary burden (MTV/TLC) (log-rank p < 0.05). SHAP directionality agreed with univariate trends. BMI showed a modest inverse association with early mortality in the 6-month survival model.

Conclusions

In our exploratory analysis, [¹⁸F]FDG-uptake within medullary concordant lesions was linked to both response and survival, while CXCR4-expressing medullary volume and sDmax added survival information. Concordance-aware, lesion-level quantification from dual-tracer PET/CT might present as a promising approach to aid risk stratification for CXCR4-directed RPT. However, initial findings of our hypothesis generating analysis warrant prospective validation in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Multiple MyelomaPositron Emission Tomography Computed TomographyRadiopharmaceuticalsBiomarkers, TumorHumansPrognosisFemaleMaleAgedMiddle AgedFluorodeoxyglucose F18Retrospective StudiesTreatment OutcomePeptides, CyclicCoordination ComplexesAged, 80 and over

Stichwörter der Autor:innen

CXCR4-RPTDual-tracer PETLesion-level quantificationPrognosis biomarker

Substanzen

Receptors, CXCR4RadiopharmaceuticalsCXCR4 protein, human68Ga-pentixaforFluorodeoxyglucose F18Biomarkers, TumorPeptides, CyclicCoordination Complexes

Autor:innen und Institutionen

  • Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. Xiang.li@meduniwien.ac.at.
  • Department of Nuclear Medicine, Beijing Chest Hospital, Capital Medical University, Beijing, China. Xiang.li@meduniwien.ac.at.

ORCID-Profile: Xiang Li

Förderung

  • Medical University of Vienna

Zitieren

APA

Xue, S., Kraus, S., Enke, J. S., Michalski, K., Hacker, M., Einsele, H., Buck, A. K., Lapa, C., Li, X., & Dreher, N. (2026). Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy. European Journal of Nuclear Medicine and Molecular Imaging, 53(7), 4560-4571. https://doi.org/10.1007/s00259-026-07814-5

Vancouver

Xue S, Kraus S, Enke JS, Michalski K, Hacker M, Einsele H, et al. Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(7):4560-4571. doi:10.1007/s00259-026-07814-5

BibTeX
@article{Xue2026,
  author = {Xue, Song and Kraus, Sabrina and Enke, Johanna S and Michalski, Kerstin and Hacker, Marcus and Einsele, Hermann and Buck, Andreas K and Lapa, Constantin and Li, Xiang and Dreher, Niklas},
  title = {Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {7},
  pages = {4560--4571},
  doi = {10.1007/s00259-026-07814-5}
}
Kostenlos starten →